Semafore Pharmaceuticals, Inc. Reports Encouraging Phase I Data at American Society of Hematology for Novel PI3K/mTOR Pathway Inhibitor
Published: Dec 08, 2009
INDIANAPOLIS--(BUSINESS WIRE)--Semafore Pharmaceuticals today reported encouraging data from a Phase I dose-escalation trial of SF1126 in patients with relapsed and refractory myeloma. SF1126 is a novel small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival. PI3K is commonly altered in human cancers, making inhibition of the target attractive for cancer therapy. Data were presented during the 51st American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.